A method of treating a disease or a disorder associated with abnormal cellular activities, wherein the disease is non-small cell lung cancer or prostate cancer, and wherein an ephrin, KDR, Flt-1, EGFR, or ErbB2 receptor tyrosine kinase is implicated, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a compound of Formula I,
- or a single stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt thereof, wherein,
- R1 is methyl;
- R2 is selected from halogen, trihalomethyl, —CN, —NH2, —NO2, —OR3, —N(R3)R4, —S(O)0-2R4, —SO2N(R3)R4, —CO2R3, —C(═O)N(R3)R4, —N(R3)SO2R4, —N(R3)C(═O)R3, —N(R3)CO2R4, —C(═O)R3, lower alkyl, lower alkenyl, and lower alkynyl;
- R3 is —H or R4;
- R4 is selected from lower alkyl;
- lower alkyl substituted with one, two, or three halogen;
- aryl;
- aryl substituted with one, two, or three halogen;
- and unsubstituted lower arylalkyl;
- or
- R3 and R4, when taken together with a common nitrogen to which they are attached, form morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl optionally substituted by one, two, or three alkyl;
- q is 0, 1, 2, 3, 4, or 5;
- Z is —NR5—;
- R5 is —H;
- M1-M2-M3-M4- together are according to formula II:
- wherein X1, X2, and optionally X3, represent the atoms of a saturated bridged ring system, said saturated bridged ring system containing up to three annular heteroatoms represented by any of X1, X2, and X3;
- wherein,
- each X1is independently selected from —C(R6)R7—, —O—, —S(O)0-2—, and —NR8—;
- each X2 is independently a bridgehead methine optionally substituted with R6, or a bridgehead nitrogen;
- each X3 is independently selected from —C(R6)R7—, —O—, —S(O)0-2—, and —NR8—;
- provided, for X1, X2, and X3, there are no nitrogen-nitrogen annular bonds nor geminal di-nitrogen substitutions;
- E is absent;
- Y is —CH2— provided that Y is not directly attached to any heteroatom represented by X1, X2 or X3;
- m and p are each independently 1, 2, 3, or 4;
- n is 0, 1, or 2, when n is zero, then there is a direct single bond between the two bridgehead X2's;
- R6 and R7 are each independently selected from —H, halogen, trihalomethyl, —CN, —NH2, —NO2, —OR3, —N(R3)R4, —S(O)0-2R4, —SO2N(R3)R4, —CO2R3, —C(O)N(R3)R4, —N(R3)SO2R4, —N(R3)C(O)R3, —NCO2R3, —C(O)R3, lower alkyl, aryl, and unsubstituted lower arylalkyl;
- or
- R6 and R7, when taken together are oxo;
- or
- R6 and R7, when taken together with a common carbon to which they are attached, form a three- to seven-membered spirocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P and wherein the spirocyclic ring is optionally substituted with one or two alkyl;
- and
- R8 is selected from R3, —SO2N(R3)R4, —CO2R3, —C(O)N(R3)R4, —SO2R4, and —C(O)R3;
- with the proviso that when Y is a C1-3 alkylene linker, E is absent, Z is —NH— or —N(CH3)—, R1 is a C1-3 alkyl, R2 is —H or halogen, n=0, and the atoms X1 of one bridge of the saturated bridged ring system, when combined with both bridgehead atoms, X2, of the saturated bridged ring system, represent:
- either a pyrrolidine ring or a piperidine ring, and any atom, X1 or X2, of either of said pyrrolidine ring or said piperidine ring is attached to Y;
- then the other bridge of said saturated bridged ring system cannot be any one of —OC(O)CH2—, —CH2OC(O)—, —OC(O)CH2CH2—, —CH2OC(O)CH2—, —CH2CH2OC(O)—, —OC(O)CH2NH—, —OC(O)CH2N(C1-4alkyl)-, and —OC(O)CH2O—;
- and
- either a piperazine ring or a 4-(C1-4 alkyl)-piperazine ring, and any atom, X1 or X2, of either of said piperazine ring or said 4-(C1-4 alkyl)-piperazine ring is attached to Y;
- then the other bridge of said saturated bridged ring system, only when attached via the 2- and the 3-position of either of said piperazine ring or said 4-(C1-4 alkyl)-piperazine ring, cannot be one of —CH2OC(O)CH2—, —CH2CH2OC(O)—, and either of the two aforementioned bridges substituted by one or two C1-2alkyl groups;
- and
- a piperazine ring, and any atom, X1 or X2, of said piperazine ring is attached to Y;
- then the other bridge of said saturated bridged ring system, only when attached via the 3- and the 4-position of said piperazine ring, cannot be —C(O)OCH2CH2—, —CH2OC(O)CH2—, —C(O)OCH2CH2— substituted with one or two C1-2 alkyl groups, or —CH2OC(O)CH2— substituted with one or two C1-2 alkyl groups (but only when the four above mentioned bridges are attached to the 3-position of said piperazine ring via their left-hand end as depicted above);
- and
- a 2-oxomorpholine ring, said 2-oxomorpholine ring attached to Y via its 4-position;
- then the other bridge of said saturated bridged ring system, only when attached via the 5- and the 6-position of said 2-oxomorpholine ring, cannot be one of —(CH2)g—, —CH2WCH2—, —CH2WCH2CH2—, and —CH2CH2WCH2—, wherein W is —O—, —S(O)0-2—, —NH—, or —N(C1-4 alkyl)- and wherein g is 2, 3, or 4;
- optionally together with a pharmaceutically acceptable carrier.